The prevalence of multisystem inflammatory syndrome in children (MIS-C) has 
increased since the coronavirus disease 2019 (COVID-19) pandemic started. This 
study was aimed to describe clinical manifestation and outcomes of MIS-C 
associated with COVID-19. This systematic review and meta-analysis were 
conducted on all available literature until July 3rd, 2020. The screening was 
done by using the following keywords: ("novel coronavirus" Or COVID-19 or severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus) and 
("MIS-C" or "multisystem inflammatory" or Kawasaki). Data on gender, ethnicity, 
clinical presentations, need for mechanical ventilation or admission to 
intensive care unit (ICU), imaging, cardiac complications, and COVID-19 
laboratory results were extracted to measure the pooled estimates. Out of 314 
found articles, 16 articles with a total of 600 patients were included in the 
study, the most common presentation was fever (97%), followed by 
gastrointestinal symptoms (80%), and skin rashes (60%) as well as shock (55%), 
conjunctivitis (54%), and respiratory symptoms (39%). Less common presentations 
were neurologic problems (33%), and skin desquamation (30%), MIS-C was slightly 
more prevalent in males (53.7%) compared to females (46.3%). The findings of 
this meta-analysis on current evidence found that the common clinical 
presentations of COVID-19 associated MIS-C include a combination of fever and 
mucocutaneous involvements, similar to atypical Kawasaki disease, and multiple 
organ dysfunction. Due to the relatively higher morbidity and mortality rate, it 
is very important to diagnose this condition promptly.